Natriuretic peptides in cardiovascular diseases: Current use and perspectives

European Heart Journal

Volumn 35, Issue 7, 2014, Pages

  Volpe, Massimo ^a,b   Rubattu, Speranza ^a,b   Burnett, John ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c MAYO CLINIC   (United States)

Author keywords

ARNi; Cardiovascular diseases; Genetics; Natriuretic peptides; Natriuretic peptides analogues; NEP inhibitors

Indexed keywords

ARNI; CARDIOVASCULAR DISEASES; GENETICS; NATRIURETIC PEPTIDES; NATRIURETIC PEPTIDES ANALOGUES; NEP INHIBITORS;

CARDIOVASCULAR DISEASES; HUMANS; NATRIURETIC PEPTIDES; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT;

EID: 84894256771     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht466     Document Type: Review

References (92)

1. Levis ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339: 321-328.
2. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12:131-142.
3. Rubattu S, Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens 2001; 19:1923-1931.
4. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, Macheret F, Huntley BK, Burnett JC Jr, Ikeda Y. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem 2011;57:864-873.
5. Chauhan SD, Hobbs AJ, Ahluwalia A. C-type natriuretic peptide: new candidate for endothelium-derived hyperpolarizing factor. Int J Biochem Cell Biol 2004;36: 1878-1881.
6. Kuhn M. Molecular physiology of natriuretic peptide signaling. Basic Res Cardiol 2004; 99:76-82.
7. Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M.NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med 2010;88:889-897.
8. Proctor KG, Bealer SL. Selective antagonism of hormone-induced vasoconstriction by synthetic atrial natriuretic factor in the rat microcirculation. Circ Res 1987;61: 42-49.
9. Woods RL, Smolich JJ. Regional blood flow effects of ANP in conscious dogs: preferential gastrointestinal vasoconstriction. Am J Physiol 1991;261(6 Pt 2): H1961-H1969.
10. Focaccio A, Volpe M, Ambrosio G,LemboG, Pannain S, Rubattu S, Enea I, Pignalosa S, Chiariello M. Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 1993;87:192-198.
11. Bruneau BG, de Bold AJ. Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1. Cardiovasc Res 1994;28:1519-1525.
12. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use and implication in cardiovascular diseases. Am J Hypertens 2008;21:733-741.
13. Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, Levy D, Newton-Cheh C,Wang TJ, Benjamin EJ, Vasan RS. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 2006;113:938-945.
14. Molkentin JD. A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest 2003;111:1275-1277.
15. Calvieri C, Rubattu S, Volpe M. Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. J Mol Med 2012; 90:5-13.
16. Tajima M, Bartunek J,Weinberg EO, Ito N, Lorell BH. Atrial natriuretic peptide has different effects on contractility and intracellular pH in normal and hypertrophied myocytes from pressure-overloaded hearts. Circulation 1998;98:2760-2764.
17. Bordicchia M, Liu D, Amri E-Z, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012;122:1022-1036.
18. Daniels LB. Natriuretic peptides and assessment of cardiovascular disease risk in asymptomatic persons. Curr Cardio Risk Rep 2010;4:120-127.
19. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T,Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663.
20. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293: 1609-1616.
21. Barbato A, Sciarretta S, Marchitti S, Iacone R, Di Castro S, Stanzione R, Cotugno M, Ippolito R, Palmieri L, Calvieri C, Battistoni A, Volpe M, Strazzullo P, Rubattu S. Aminoterminal natriuretic peptides and cardiovascular risk in an Italian male adult cohort. Int J Cardiol 2011;152:245-246.
22. McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc 2011;86:1154-1160.
23. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk. Systematic Reviewand Meta-Analysis of 40 Prospective Studies. Circulation 2009;120:2177-2187.
24. Wannamethee G,Welsh P, Lowe GD, Gudnason V, Di Angelantonio E, Lennon L, Rumley A, Whincup PH, Sattar N. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 2011;58:56-64.
25. Welsh P, Doolin O, Willeit P, Packard C, Macfarlane P, Cobbe S, Gudnason V, Di Angelantonio E, Ford I, Sattar N. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J 2013;34:443-450.
26. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28: 22-30.
27. ZhouW, Ni Z, Yu Z, Shi B,Wang Q. Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease. Eur J Int Med 2012;23:539-544.
28. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585.
29. Seronde MF, Gayat E, Logeart D, Lassus J, Laribi S, Boukef R, Sibellas F, Launay JM, Manivet P, Sadoune M, Nouira S, Cohen Solal A, Mebazaa A. Great Network. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Intern J Cardiol 2013;168:3404-3411.
30. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola V-P, van Kimmenade R, Pathak A, Mueller T, Di Somma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebaza A for the Great-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013;168:2186-2194.
31. Boerrigter G, Costello-Boerrigter LC, Burnett JC Jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin 2009;5:501-514.
32. Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Rao MAE, Trimarco B, Condorelli M. Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: A 15-year prospective follow-up study. Clin Cardiol 2010; 33:700-707.
33. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:1498-1506.
34. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66-74.
35. Bhardwaj A, Januzzi JL. Natriuretic peptide-guided management of acutely destabilized heart failure. Rationale and treatment algorithm. Critical Pathways Cardiol 2009;8:146-150.
36. Motiwala SR, Januzzi JL. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin Pharm Therap 2013;93:57-67.
37. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
38. Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS ONE 2013;8: e58287.
39. Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlö f B, Hildebrandt PR. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 2006;24:1531-1539.
40. PagetV, Legedz L, Gaudebout N, Girerd N, Bricca G, Milon H, VincentM, Lantelme P. N-terminal pro-brain natriuretic peptide. A powerful predictor of mortality in hypertension. Hypertension 2011;57:702-709.
41. Kaleghi M, Al-Omari MA, Kondragunta V, Morgenthaler NG, Struck J, Bergmann A, Mosley TH, Kuoo IJ. Relation of plasma midregional natriuretic peptide to target organ damage in adults with systemic hypertension. Am J Cardiol 2009;103: 1255-1260.
42. Noman A, George J, Struthers A.A new use for B-type natriuretic peptide: to detect myocardial ischemia in non-heart failure patients. Br J Diabetes Vasc Dis 2010;10: 78-82.
43. Casco VH, Veinot JP, Kuroski de Bold MLK, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002;50:799-809.
44. Barbato E, Rubattu S, Bartunek J, Berni A, Sarno G, Vanderheyden M, Delrue L, Zardi D, Pace B, De Bruyne B, Coluccia R, WijnsW, Volpe M. Role of cardiac natriuretic peptides in human coronary atherosclerosis. Atherosclerosis 2009;206: 258-264.
45. Squire IB, O'Brien RJ, Demme B, Davies JE, Ng LL. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci 2004;107:309-316.
46. Makikallio AM, Makikallio TH, Korpelainen JT, Vuolteenaho O, Tapanainen JM, Ylitalo K, Sotaniemi KA, Huikuri HV, Myllyla VV. Natriuretic peptides and mortality after stroke. Stroke 2005;36:1016-1020.
47. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal proBtype natriuretic peptide and long-term mortality in stable coronary heart disease. New Engl J Med 2005;352:666-675.
48. Harutyunyan MJ, Mathiasen AB, Winkel P, Gotze JP, Hansen JF, Hildebrandt P, Jensen JB, Hilden J, Jespersen CM, Kjoller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease: a prognostic study within the CLARICOR trial. Scand J Clin Lab Invest 2011;71:52-62.
49. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012;125:233-240.
50. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50: 234-236.
51. Ray SG. Natriuretic peptides in heart valve disease. Heart 2006;92:1194-1197.
52. Vanderheyden M, Goethals M, Verstreken S, De Bruyne B, Muller K, Van Schuerbeeck E, Bartunek J.Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44:2349-2354.
53. Detaint D, Messika-Zeitoun D, Avierinos J-F, Avierinos JF, Scott C, Chen H, Burnett JC Jr, Enriquez-Sarano M. B-type natriuretic peptide in organic mitral regurgitation. Circulation 2005;11:2391-2397.
54. The International Consortium for Blood Pressure Genome-Wide association studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sõber S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH, Sjögren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, Lehtimäki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uiterwaal CS, Adeyemo A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND; CARDIoGRAMConsortium; CKDGen Consortium; KidneyGenConsortium; EchoGen Consortium; CHARGE-HF Consortium, Aspelund T, Garcia M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC, Kähönen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Bolton JA, Kö ttgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grässler J, Groop L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Soler Artigas M, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD,RosengrenA, Thelle DS, CorsiAM,Singleton A, ForresterT, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y, Ogihara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stanc?áková A, Raffel LJ, Yao J, Kathiresan S, O'Donnell CJ, Schwartz SM, Ikram MA, Longstreth WT Jr, Mosley TH, Seshadri S, Shrine NR, Wain LV, Morken MA, Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani KR, Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ, Lyytikäinen LP, Soininen P, Tukiainen T, Würtz P, Ong RT, Dö rr M, Kroemer HK, Vö lker U, Vö lzke H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MV, Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, Schwarz PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Tai ES, Cooper RS, Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen D, Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker PM, Bandinelli S, Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller PP, Elosua R, Soranzo N, Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boerwinkle E, Vasan RS, Boehnke M, Larson MG, Järvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn CM, Newton-Cheh C, Levy D, Caulfield MJ, Johnson T. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478:103-109.
55. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009;41:348-353.
56. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, TayWT, Chen C-H, Zhang Y, Yamamoto K, Katsuya T, Yokota M, Kim YJ, Ong RT, Nabika T, Gu D, Chang LC, Kokubo Y, Huang W, Ohnaka K, Yamori Y, Nakashima E, Jaquish CE, Lee JY, Seielstad M, Isono M, Hixson JE, Chen YT, Miki T, Zhou X, Sugiyama T, Jeon JP, Liu JJ, Takayanagi R, Kim SS, Aung T, Sung YJ, Zhang X, Wong TY, Han BG, Kobayashi S, Ogihara T, Zhu D, Iwai N, Wu JY, Teo YY, Tai ES, Cho YS, He J. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 2011;43:531-538.
57. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M, Stella P. Association of atrial natriuretic and type-A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006;48:499-505.
58. Xue H,Wang S,Wang H, Sun K, Song X, ZhangW, Fu C, Han Y, Hui R. Atrial natriuretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension. Clin Sci (Lond) 2007;114:131-137.
59. Sciarretta S, Marchitti S, Bianchi f, Moyes A, Barbato E, Di Castro S, Stanzione R, Cotugno M, Castello L, Calvieri C, Iberini I, Sadoshima J, Hobbs AJ, Volpe M, Rubattu S. The C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptorCsignaling. Circ Res 2013;112:1355-1364.
60. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, Gigante B, Pirisi A, Brunetti E, Volpe M. Atrial natriuretic peptide gene polymorphisms and the risk of ischemic stroke in humans. Stroke 2004;35:814-818.
61. Lynch AI, Claas SA, Arnett DK. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep 2009;11:35-42.
62. Barbato E, Bartunek J, Mangiacapra F, Sciarretta S, Stanzione R, Delrue L, Cotugno M, Marchitti S, Iaccarino G, Sirico G, Di Castro S, Evangelista A, Lambrechts D, Sinnaeve P, De Bruyne B, Van De Werf F, Janssens S, Fox K-A-A, Wijns W, Volpe M, Rubattu S. Influence of rs5065 atrial natriuretic peptide gene variant oncoronary artery disease. J Am Coll Cardiol 2012;59:1763-1770.
63. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 2008; 299:296-307.
64. Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett JC Jr. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 2011;58:629-636.
65. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravat DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS,Wong ND,WooD, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: Heart disease and stroke statistics-2013 update.Areport from the American Heart Association. Circulation 2013;127:143-152.
66. Volpe M, Mele AF, Indolfi C, De Luca N, Lembo G, Focaccio A, Condorelli M, Trimarco B. Haemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. J Am Coll Cardiol 1987;10:787-793.
67. Ando S, Ramhan MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26(6 Pt 2):1160-1166.
68. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnesGT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
69. Corti R, Burnett JCJr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104: 1856-1862.
70. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-111.
71. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 41:383-389.
72. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Kin TH, ZhengW, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401-414.
73. Ruilope LM, Dukat A, BöhmM, LacourcièreY, Gong J, LefkowitzMP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-1266.
74. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopetidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013;34:886-893.
75. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-926.
76. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-620.
77. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 1998;351:1657-1658.
78. Kangawa K, Tawaragi Y, Oikawa S, Mizuno A, Sakuragawa Y, Nakazato H, Fukuda A, Minamino N, Matsuo H. Identification of ratgamma atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature 1984;312:152-155.
79. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, Murai K, Muanakata R, Yumino D, Meguro T, Kawana M, Nejima J, Satoh T, Mizuno K, Tanaka K, Kasanuki H, Takano T; ATTEND Investigators. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 1010;159: 949-955.
80. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure. J Am Coll Cardiol 2012;60:2305-2312.
81. Sackner-Berstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491.
82. Kelesidis I, Mazurek J, Khullar P, SaeedW, Vittorio T, Zolty R. The effect of nesiritide on renal function and other clinical parameters in patients with decompensated heart failure and preserved ejection fraction. Congest Heart Fail 2012;18:158-164.
83. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV. For the prospective comparison of ARNi with ARB on Management of Heart Failure with preserved ejection fraction (PARAMOUNT) Investigators. Lancet 2012;380: 1387-1395.
84. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR, on behalf of the PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Failure 2013;15:1062-1073.
85. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008;29:1485-1494.
86. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007;49: 667-674.
87. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S. J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370:1483-1493.
88. Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, Schears RM, Redfield MM, Simari RD, Lerman A, Cataliotti A, Burnett JC Jr. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart 2009;95:1315-1319.
89. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Kimura H, Shiono M, Takayama T, Hirayama A. Continuos low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: The NU-HIT (Nihon University working group study of low-dose HumanANPInfusion therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 2010;55:1844-1851.
90. Mentzer RM, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Luber JM Jr, Smedira NG. NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. J Am Coll Cardiol 2007;49:716-726.
91. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double blind placebo-controlled pilot study. Circulation 2007;116:I134-I138.
92. Sezai A,Wakui S, Akiyama K, Hata M, Yoshitake I, Unosawa S, Shiono M, Hirayama A. Myocardial protective effect of human atrial natriuretic peptide in cardiac surgery. Circulation J 2011;75:2144-2150.